African Americans Possessed High Prevalence of Comorbidities and Frequent Abdominal Symptoms, and Comprised A Disproportionate Share of Covid-19 Mortality among 9,873 Us- Hospitalized Patients Early in the Pandemic.

African Americans COVID-19 Mortality United States

Journal

Archives of internal medicine research
ISSN: 2688-5654
Titre abrégé: Arch Intern Med Res
Pays: United States
ID NLM: 9918300879806676

Informations de publication

Date de publication:
2024
Historique:
medline: 2 5 2024
pubmed: 2 5 2024
entrez: 2 5 2024
Statut: ppublish

Résumé

Identifying clinical characteristics and outcomes of different ethnicities in the US may inform treatment for hospitalized COVID-19 patients. Aim of this study is to identify predictors of mortality among US races/ethnicities. We retrospectively analyzed de-identified data from 9,873 COVID-19 patients who were hospitalized at 15 US hospital centers in 11 states (March 2020-November 2020). Main Outcomes and Measures: The primary outcome was to identify predictors of mortality in hospitalized COVID-19 patients. Among the 9,873 patients, there were 64.1% African Americans (AA), 19.8% Caucasians, 10.4% Hispanics, and 5.7% Asians, with 50.7% female. Males showed higher in-hospital mortality (20.9% vs. 15.3%, p=0.001). Non- survivors were significantly older (67 vs. 61 years) than survivors. Patients in New York had the highest in-hospital mortality (OR=3.54 (3.03 - 4.14)). AA patients possessed higher prevalence of comorbidities, had longer hospital stay, higher ICU admission rates, increased requirement for mechanical ventilation and higher in-hospital mortality compared to other races/ethnicities. Gastrointestinal symptoms (GI), particularly diarrhea, were more common among minority patients. Among GI symptoms and laboratory findings, abdominal pain (5.3%, p=0.03), elevated AST (n=2653, 50.2%, p=<0.001, OR=2.18), bilirubin (n=577, 12.9%, p=0.01) and low albumin levels (n=361, 19.1%, p=0.03) were associated with mortality. Multivariate analysis (adjusted for age, sex, race, geographic location) indicates that patients with asthma, COPD, cardiac disease, hypertension, diabetes mellitus, immunocompromised status, shortness of breath and cough possess higher odds of in-hospital mortality. Among laboratory parameters, patients with lymphocytopenia (OR2=2.50), lymphocytosis (OR2=1.41), and elevations of serum CRP (OR2=4.19), CPK (OR2=1.43), LDH (OR2=2.10), troponin (OR2=2.91), ferritin (OR2=1.88), AST (OR2=2.18), D-dimer (OR2=2.75) are more prone to death. Patients on glucocorticoids (OR2=1.49) and mechanical ventilation (OR2=9.78) have higher in-hospital mortality. These findings suggest that older age, male sex, AA race, and hospitalization in New York were associated with higher in-hospital mortality rates from COVID-19 in early pandemic stages. Other predictors of mortality included the presence of comorbidities, shortness of breath, cough elevated serum inflammatory markers, altered lymphocyte count, elevated AST, and low serum albumin. AA patients comprised a disproportionate share of COVID-19 death in the US during 2020 relative to other races/ethnicities.

Sections du résumé

Background and aim UNASSIGNED
Identifying clinical characteristics and outcomes of different ethnicities in the US may inform treatment for hospitalized COVID-19 patients. Aim of this study is to identify predictors of mortality among US races/ethnicities.
Design Setting and participants UNASSIGNED
We retrospectively analyzed de-identified data from 9,873 COVID-19 patients who were hospitalized at 15 US hospital centers in 11 states (March 2020-November 2020). Main Outcomes and Measures: The primary outcome was to identify predictors of mortality in hospitalized COVID-19 patients.
Results UNASSIGNED
Among the 9,873 patients, there were 64.1% African Americans (AA), 19.8% Caucasians, 10.4% Hispanics, and 5.7% Asians, with 50.7% female. Males showed higher in-hospital mortality (20.9% vs. 15.3%, p=0.001). Non- survivors were significantly older (67 vs. 61 years) than survivors. Patients in New York had the highest in-hospital mortality (OR=3.54 (3.03 - 4.14)). AA patients possessed higher prevalence of comorbidities, had longer hospital stay, higher ICU admission rates, increased requirement for mechanical ventilation and higher in-hospital mortality compared to other races/ethnicities. Gastrointestinal symptoms (GI), particularly diarrhea, were more common among minority patients. Among GI symptoms and laboratory findings, abdominal pain (5.3%, p=0.03), elevated AST (n=2653, 50.2%, p=<0.001, OR=2.18), bilirubin (n=577, 12.9%, p=0.01) and low albumin levels (n=361, 19.1%, p=0.03) were associated with mortality. Multivariate analysis (adjusted for age, sex, race, geographic location) indicates that patients with asthma, COPD, cardiac disease, hypertension, diabetes mellitus, immunocompromised status, shortness of breath and cough possess higher odds of in-hospital mortality. Among laboratory parameters, patients with lymphocytopenia (OR2=2.50), lymphocytosis (OR2=1.41), and elevations of serum CRP (OR2=4.19), CPK (OR2=1.43), LDH (OR2=2.10), troponin (OR2=2.91), ferritin (OR2=1.88), AST (OR2=2.18), D-dimer (OR2=2.75) are more prone to death. Patients on glucocorticoids (OR2=1.49) and mechanical ventilation (OR2=9.78) have higher in-hospital mortality.
Conclusion UNASSIGNED
These findings suggest that older age, male sex, AA race, and hospitalization in New York were associated with higher in-hospital mortality rates from COVID-19 in early pandemic stages. Other predictors of mortality included the presence of comorbidities, shortness of breath, cough elevated serum inflammatory markers, altered lymphocyte count, elevated AST, and low serum albumin. AA patients comprised a disproportionate share of COVID-19 death in the US during 2020 relative to other races/ethnicities.

Identifiants

pubmed: 38694760
doi: 10.26502/aimr.0163
pmc: PMC11062622
doi:

Types de publication

Journal Article

Langues

eng

Pagination

27-41

Déclaration de conflit d'intérêts

Declarations Conflict-of-interest statement The authors declare no conflicts of interest.

Auteurs

Hassan Ashktorab (H)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Antonio Pizuorno (A)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Lakshmi Gayathri Chirumamilla (LG)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Folake Adeleye (F)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Maryam Mehdipour Dalivand (MM)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Zaki A Sherif (ZA)

Department of Pathology and Cancer Center, Department of Biochemistry & Molecular Biology, Howard University College of Medicine, Washington DC, USA.

Gholamreza Oskrochi (G)

College of Engineering and Technology, American University of the Middle East, Kuwait.

Suryanarayana Reddy Challa (SR)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Boubini Jones-Wonni (B)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Sheldon Rankine (S)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Chiamaka Ekwunazu (C)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Abigail Banson (A)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Rachel Kim (R)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Chandler Gilliard (C)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Elizabeth Ekpe (E)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Nader Shayegh (N)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Constance Nyaunu (C)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Chidi Martins (C)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Ashley Slack (A)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Princess Okwesili (P)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Malachi Abebe (M)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Yashvardhan Batta (Y)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Do Ly (D)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Ogwo Valarie (O)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Tori Smith (T)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Kyra Watson (K)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Oluwapelumi Kolawole (O)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Sarine Tahmazian (S)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Sofiat Atoba (S)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Myra Khushbakht (M)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Gregory Riley (G)

Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.

Warren Gavin (W)

Division of General Internal Medicine and Geriatrics, Indiana University School of Medicine, IN, USA.

Areeba Kara (A)

Division of General Internal Medicine and Geriatrics, Indiana University School of Medicine, IN, USA.

Manuel Hache-Marliere (M)

Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.

Leonidas Palaiodimos (L)

Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.

Vishnu R Mani (VR)

Department of Trauma, Acute and Critical Care Surgery, Duke University Medical Center, NC, USA.

Aleksandr Kalabin (A)

Department of Surgery, Columbia University College of Physicians and Surgeons at Harlem Hospital, NY, USA.

Vijay Reddy Gayam (VR)

Department of Medicine, Interfaith Medical Center, NY, USA.

Pavani Reddy Garlapati (PR)

Department of Medicine, Interfaith Medical Center, NY, USA.

Joseph Miller (J)

Departments of Emergency Medicine and Internal Medicine, Henry Ford Hospital, Detroit, MI, USA.

Fatimah Jackson (F)

Department of Pathology and Cancer Center, Department of Biochemistry & Molecular Biology, Howard University College of Medicine, Washington DC, USA.

John M Carethers (JM)

Division of Gastroenterology and Hepatology, Department of Internal Medicine; Department of Human Genetics and Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

Vinod Rustgi (V)

Division of Gastroenterology and Hepatology, Robert Wood Johnson University Hospital - New Brunswick, NJ.

Hassan Brim (H)

Department of Pathology and Cancer Center, Department of Biochemistry & Molecular Biology, Howard University College of Medicine, Washington DC, USA.

Classifications MeSH